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The aim of this study was to examine antibiotic resistance profiles and diversity of β-lactamases in Escherichia coli 
present within the population and the potential spread of resistant E. coli into the receiving environment using 
city-scale sewage surveillance. In E. coli isolates from ECC plates without antibiotics from ten influent samples (n 
= 300), highest resistance was observed against ampicillin (16.6%), sulfamethoxazole (9.7%) and trimethoprim 
(9.0%), while in effluent samples (n = 262) it was against sulfamethoxazole (11.8%), ampicillin (11.5%) and 
tetracycline (8.8%). All isolates (n = 123) obtained on cefotaxime-containing plates were multidrug-resistant. 
Several clinically important antibiotic resistance genes (ARGs) were detected in 46 E. coli isolates subjected to 
whole-genome sequencing, including carbapenemases like NDM-6, VIM-1 and OXA-48-variant, as well as tige-
cycline resistance gene tet(X4). CTX-M-15 was the most prevalent (42.9%) extended-spectrum β-lactamase 
among cefotaxime-resistant isolates, followed by CTX-M-27 (31.4%) and CTX-M-14 (17.1%), resembling clinical 
prevalence in Norway. Most of the sequenced isolates carried other clinically relevant ARGs, such as dfrA17, sul1, 
sul2, tet(A), aph(6)-Id, aph(3’’)-Ib and aadA5. Sixteen different sequence types (STs) were identified, including 
ST131 (39.1%), ST38 (10.9%) and ST69 (8.7%). One E. coli isolate belonging to novel ST (ST11874) carried 
multiple virulence factors including genotoxin, salmochelin, aerobactin and yersiniabactin, suggesting that this 
isolate has potential to cause health concerns in future. Our study reveals presence of clinically relevant ARGs 
like blaNDM-6 and tet(X4) in pathogenic strains, which have so far not been reported from the clinics in Norway. 
Our study may thus, provide a framework for population-based surveillance of antibiotic resistance.   
1. Introduction 
Clinically relevant β-lactamases carried by the members of family 
Enterobacteriaceae represent an emerging public health threat, for which 
research and development of new antibiotics is urgently needed (WHO, 
2017). Extended-spectrum β-lactamases (ESBLs) and carbapenemases 
are groups of enzymes that hydrolyze critical important β-lactam anti-
biotics, such as third-generation cephalosporins (3GCs) and carbape-
nems (Pfeifer et al., 2010). ESBL-producing Escherichia coli are a major 
cause of community-acquired infections, especially in Europe (Mathers 
et al., 2015). E. coli are mostly commensals and usually part of human 
gut microbiota, while some opportunistic, pathogenic strains can cause 
both common and severe infections. Pathogenic strains belonging to 
sequence type (ST) 131, 38 and 405, represents high-risk clones of sig-
nificant public health concern that usually encode β-lactamases (Manges 
et al., 2019; Peirano and Pitout, 2019). Dissemination of specific clones 
and epidemic plasmids in clinical and community settings is important 
factor contributing towards the emergence of ESBLs in Europe (Bevan 
et al., 2017). 
In Europe, the prevalence of clinical E. coli isolates resistant to 3GCs 
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is higher in south-eastern countries compared to northern countries 
(ECDC, 2020). For instance, Italy represents a high-risk country in terms 
of antibiotic resistance due to, in part, extensive use of antibiotics (EMA, 
2020). The prevalence of invasive E. coli isolates resistant to 3GCs in 
Italy was 30.9% in 2019 (ECDC, 2020). In contrast, Norway is a country 
with a low burden of antibiotic resistance in clinics (ECDC, 2020). In 
Norway, the clinical prevalence of ESBL-positive E. coli isolates in 2019 
was 7.1% and 3.0% from blood and urine, respectively (NORM/-
NORM-VET, 2020). Accordingly, the occurrence of ESBL-producing 
E. coli in the environment in Norway was also low (Bevan et al., 2017; 
Grevskott et al., 2017). 
Sewage contains a collection of stools from the population connected 
to the sewage system (Hutinel et al., 2019; Huijbers et al., 2020). Effi-
cient treatment is crucial for limiting the load of untreated sewage 
released into receiving environments. A major cause for the spread of 
antibiotic resistance is the partial lack of proper infrastructure for 
sewage treatment, especially in low- and middle-income countries 
(Lamba et al., 2018). Sewage serves as an important source for intro-
ducing clinically relevant pathogens and antibiotic resistance genes 
(ARGs) into the environment (Karkman et al., 2019; Marathe et al., 
2017, 2013). This is of particular concern, since the efficiency for 
removing bacteria in sewage treatment systems in Norway is low (VKM, 
2020). 
Currently, several national surveillance programs for antibiotic 
resistance in clinical and veterinary settings exists. However, surveil-
lance of antibiotic resistance in the community and the environment is 
lacking (Marano et al., 2020). Population-based sewage surveillance has 
emerged as a promising approach for studying the prevalence of anti-
biotic resistance in the community (Hutinel et al., 2019; Huijbers et al., 
2020). Sewage makes it possible to analyze E. coli and associated anti-
biotic resistance within the population living in a specific area. The 
prevalence of ESBL-positive E. coli strains can be examined by targeting 
cefotaxime-resistant strains, which are frequently associated with 
multidrug-resistance (Marano et al., 2020). Thus, this approach can 
provide up-to-date surveillance of antibiotic resistance in E. coli present 
in the population, which can be used to alert the local authorities in case 
of emergence of rare or new resistance threats. In Norway, surveillance 
of antibiotic resistance in E. coli isolates obtained from sewage is lacking 
(VKM, 2020). The Norwegian surveillance program for antibiotic 
resistance is largely based on a collection of data from human and ani-
mal health sectors (NORM/NORM-VET, 2020), thus, systematic data on 
the prevalence of resistance in the community and environmental set-
tings is lacking. 
The aim of this study was to understand the prevalence of antibiotic 
resistance and diversity of ESBLs in E. coli present in the population in 
Bergen, Norway using city-scale sewage surveillance, as well as study 
the potential spread of resistant E. coli into receiving aquatic environ-
ment through analysis of the treated effluents. We further compared the 
resistance profiles of E. coli isolates from sewage and the clinical E. coli 
isolates from Norway. 
2. Materials and methods 
2.1. Collection of sewage samples 
Composite samples, representing a 24-hour period, from both 
influent and treated effluent were collected on two occasions (August 5th 
and October 7th, 2020) from five sewage treatment plants (STPs) located 
in Bergen city in Norway (Table 1). The largest STP is Flesland (Fle) 
serving 152,000 inhabitants, which receives sewage from industries as 
well as the international airport. Holen (Hol) is the second largest STP 
serving 132,000 inhabitants and receives sewage from a 933-bed hos-
pital. However, the proportion of industry, airport and hospital input is 
unknown. Knappen (Kn), Kverneviken Åsane (KvÅ) and Ytre-Sandviken 
(YS) serve 60,000, 56,000 and 44,000 inhabitants, respectively. 
2.2. Isolation and identification of Escherichia coli 
Sewage samples were transported to the laboratory in sterile con-
tainers at 4 ◦C, and the cultivation-based analyses were initiated within 
6 h after collection. The samples were serially diluted ten-fold with 
sterile saline (0.85% NaCl) before plating on ECC (CHROMagar™, 
France) chromogenic media, with and without 2 μg/mL cefotaxime 
(Sigma-Aldrich, Germany), and incubated at 37 ◦C for 20–22 h. E. coli 
CCUG 17620 and E. coli CCUG 73937 (Grevskott et al., 2020) were 
included as negative and positive controls, respectively, for verifying the 
ECC plates with cefotaxime. The amount of E. coli was estimated by 
counting the number of blue colonies on the ECC plates. Subsequently, 
the ratio of cefotaxime-resistant E. coli to total E. coli was calculated. 
Isolated, blue colonies were randomly picked from the ECC plates, with 
and without cefotaxime, and restreaked on Mueller-Hinton (MH) 
Orientation (CHROMagar™, France) chromogenic media and incubated 
at 37 ◦C for 20–22 h. From each sample, ten and 30 isolates were picked 
from ECC plates with and without cefotaxime, respectively. Identifica-
tion of isolates was performed using matrix-assisted laser desorption 
ionization-time of flight mass spectrometry (MALDI-TOF MS) at Institute 
of Marine Research (IMR) (Bruker Daltonics, Germany). Subsequently, 
confirmed E. coli isolates were stored at − 80 ◦C in MH broth (Oxoid, UK) 
with 20% glycerol until further use. 
2.3. Antibiotic sensitivity testing 
The resistance profile of 685 E. coli isolates was determined against 
14 antibiotics using a broth microdilution assay with Sensititre® 
EUVSEC plates (Thermo Scientific, USA) following manufacturer’s 
protocol. Each isolate was tested for ampicillin (AMP), cefotaxime 
(FOT), ceftazidime (TAZ), meropenem (MERO), gentamicin (GEN), 
nalidixic acid (NAL), ciprofloxacin (CIP), trimethoprim (TMP), sulfa-
methoxazole (SMX), tetracycline (TET), tigecycline (TGC), azithromycin 
(AZI), chloramphenicol (CHL), and colistin (COL). The plates were 
incubated at 37 ◦C for 20–22 h. The isolates were defined as susceptible 
or resistant according to the EUCAST clinical breakpoints tables v.10.0 
(EUCAST, 2020). For AZI, the minimum inhibitory concentration (MIC) 
breakpoint for Salmonella Typhi (>16 mg/L for wild-type isolates) was 
Table 1 
Overview of sewage treatment plants (STPs), capacity and type of treatment.     
Type of treatment 
STP Area Capacity (nr. of inhabitants) Moving bed biofilm reactor (MBBR) Activated sludge Chemical removal 
Ytre Sandviken Centrum and Sandviken 44,000 yes no no 
Flesland Bergen Southa 152,000 no yes no 
Kverneviken Åsane Åsane 56,000 no no yes 
Knappen Minde and Fyllingsdalen 60,000 no no yes 
Holen Centrum and Nordnesb 132,000 no yes no  
a Receives sewage from industries and international airport 
b Receives sewage from a 933-bed hospital 
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used when defining cut-off for resistant. For the remaining antibiotics 
not included in the EUCAST tables for E. coli (i.e. NAL, SMX and TET), 
the isolates were defined as resistant when growing in the highest cor-
responding antibiotic concentration. E. coli CCUG 17620 and E. coli 
CCUG 73937 (Grevskott et al., 2020) were included as negative and 
positive controls, respectively. 
2.4. DNA extraction and sequencing 
Based on phenotypic resistance profiles, 46 E. coli isolates were 
selected for genome sequencing. These isolates were grown overnight on 
MH agar (Oxoid, UK), either with or without 2 μg/mL cefotaxime 
(Sigma-Aldrich, Germany) based on the resistance profiles, at 37 ◦C. 
Genomic DNA was extracted from the isolates, using the DNeasy Blood 
and Tissue kit (Qiagen, Germany) following the manufacturer’s proto-
col. The extracted DNA was quantified, using Qubit™ 2.0 Fluorometer 
with the dsDNA BR (Broad-Range) kit and NanoDrop™ 2000 Spectro-
photometer (Thermo Scientific, USA) assay. Sequencing libraries were 
prepared using Nextera DNA Flex Library Prep kit (Illumina, USA). 
Sequencing was performed using Illumina MiSeq platform (Illumina, 
USA), with 2 × 300 bp chemistry, at the Norwegian Sequencing Centre 
(Ullevål University Hospital, Oslo, Norway). 
2.5. Genome assembly and sequencing analysis 
The raw reads generated by Illumina MiSeq were quality trimmed 
and assembled, using methods previously described (Radisic et al., 
2020). Draft genomes were annotated using the Prokaryotic Genome 
Annotation Pipeline (PGAP) v.4.13 at the National Center for Biotech-
nology Information (NCBI) (Tatusova et al., 2016). Sequence types (STs) 
were identified, using the PubMLST database (https://pubmlst.org/-
bigsdb?db=pubmlst_ecoli_achtman_seqdef). E. coli isolates with novel 
STs were submitted to Enterobase v.1.1.2 (Zhou et al., 2020) in order to 
get new ST number. The presence of ARGs was analyzed, using the 
ResFinder v.4.1 (Bortolaia et al., 2020) and comprehensive antibiotic 
resistance database (CARD) v.3.1.0 (Alcock et al., 2020). Virulence 
genes were examined using the database of “core dataset of protein se-
quences” at the virulence factors database (VFDB) (Liu et al., 2019), 
while biocide/metal resistance genes (BMRGs) were examined using the 
BacMet database v.2.0 (Pal et al., 2014). For the BacMet database, 
BMRGs were analyzed using the script BacMet-Scan.pl against the 
database of “experimentally confirmed resistance genes”. 
2.6. Collection of clinical data from the Norwegian surveillance report for 
year 2019 
Resistance data for clinical E. coli isolates, obtained from blood and 
urine, was retrieved from the Norwegian surveillance report (NORM/-
NORM-VET, 2020), which publishes annual antibiotic resistance results 
for specific microorganisms from primary diagnostics and national ref-
erences laboratories. 
3. Results 
3.1. E. coli counts in influent and effluent samples 
Cefotaxime-resistant E. coli were detected in all five influent samples 
(median 200 colony-forming unit (CFU) per mL), and three effluent 
samples (median 60 CFU/mL) in August 2020 (Supplementary Table S1) 
and all five influent and two effluent samples in October 2020 (median 
420 CFU/mL and 50 CFU/mL, respectively). Total CFU for E. coli were 
higher in influents than in effluents for all five STPs in both August and 
October sampling. The ratio of cefotaxime-resistant E. coli to total E. coli 
in influents varied between 0.3% and 4.4% and for effluents between 0% 
and 5.0%, respectively, in August samples and between 1.4% and 13.3% 
and 0–1.1%, respectively, in October samples. During the two sampling 
occasions, 685 of the 687 isolates (99.7%) were identified as E. coli. One 
isolate was identified as Citrobacter freundii, while the other isolate was 
unidentifiable, and these isolates were removed from subsequent ana-
lyses. Out of 685 E. coli isolates obtained in this study, 562 were isolated 
on non-selective plates and 123 were isolated on plates containing 
cefotaxime. 
3.2. Resistance rates in E. coli isolates 
A total of 300 and 262 E. coli isolates obtained from influent and 
effluent samples on non-selective plates, respectively, were analyzed. 
The highest prevalence of resistance among the E. coli isolates obtained 
from influents in August was observed against AMP (12.7%), followed 
by SMX (9.3%) and TMP (8.0%), while no resistance was observed for 
MERO, TGC and COL (Fig. 1). For October samples, the highest resis-
tance rate was observed for AMP (20.0%), followed by TET (10.7%), 
TMP (10.0%) and SMX (10.0%), while no resistance was observed for 
MERO, TGC and COL. Multidrug resistance (MDR), i.e. resistance against 
three or more antibiotic classes, was observed to be 7.3% for E. coli 
isolates obtained from influents during both sampling occasions. 
E. coli isolates obtained from effluents from August showed highest 
resistance against SMX (13.1%), followed by AMP (9.8%) and AZI 
(9.0%), while no resistance was observed for MERO, TGC and COL 
(Fig. 1). Among the E. coli isolates obtained from effluents collected in 
October, the highest resistance rate was observed for AMP (12.9%), 
followed by SMX (10.7%) and TET (10.0%), while no resistance was 
observed for FOT, TAZ, MERO, TGC and COL. MDR was observed in 
4.1% and 6.4% of E. coli isolates obtained from effluent samples from 
August and October, respectively. The resistance rates of E. coli isolates 
from five STPs did not differ between August and October sampling. 
3.3. Comparison of resistance patterns in E. coli isolates from sewage and 
the clinics 
Although lower overall prevalence of resistance was observed in 
isolates from sewage compared to clinical isolates, the patterns of 
resistance profiles of E. coli isolates from sewage (influents) were similar 
to those observed in isolates from clinics (blood and urine) (Supple-
mentary Table S2). In all sample types, the highest prevalence of resis-
tance was observed against AMP (43.3% for blood, 34.6% for urine and 
16.3% for influents), followed by TMP (not reported for blood, 23.8% 
for urine and 9.0% for influents) and TMP/SMX (24.6% for blood, 20.5% 
for urine and 7.0% for influents). The resistance rates against FOT and 
TAZ were higher in blood (7.2% and 6.0%, respectively) compared to 
urine (3.2% and 2.3%, respectively) and influents (2.3% and 1.3%, 
respectively). No resistance was detected against TGC, except for iso-
lates from blood (0.4%). In addition, no resistance was observed against 
MERO in isolates from all sample types. 
3.4. Resistance profiles of cefotaxime-resistant E. coli isolates obtained 
from sewage 
A total of 98 and 25 E. coli isolates obtained on cefotaxime- 
containing plates from influent and effluent samples, respectively, 
were analyzed. The highest rates of resistance among the E. coli isolates 
(n = 98) obtained from influents in August and October sampling were 
observed against AMP (100%), followed by FOT (98%) and NAL 
(64.3%), while no resistance was observed for COL (Supplementary 
Table S3). For isolates (n = 25) obtained from effluent samples, highest 
prevalence of resistance was observed towards AMP (100%) and FOT 
(100%), followed by NAL (64.0%), while no resistance was observed 
against MERO, TGC and COL (Supplementary Table S3). A higher 
prevalence of MDR E. coli isolates was observed in effluents (100%) 
compared to influents (86.7%). 
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3.5. Diversity of E. coli STs and clinically relevant β-lactamases 
Genome assembly statistics of the draft genome sequences of the 
sequenced E. coli isolates (n = 46) are presented in Supplementary 
Table S4. Among these, the prevalent sequence type was ST131 (39.1%), 
followed by ST38 (10.9%) and ST69 (8.7%) (Table 2). Four isolates were 
assigned to two novel STs, three isolates belonged to ST11873 and one 
belonged to ST11874. Most isolates carried ESBL and/or carbapenemase 
genes (Table 2). Isolate 2–331 and 2–333 obtained from influents car-
ried blaNDM-6, while isolate 2–338 and 3–349 obtained from effluents 
carried blaOXA-244 and blaVIM-1, respectively. Among the CTX-M-carrying 
isolates (n = 35), the majority harbored blaCTX-M-15 gene (42.9%), fol-
lowed by blaCTX-M-27 (31.4%) and blaCTX-M-14 (17.1%), resembling the 
clinical prevalence of ESBLs in E. coli in Norway (NORM/NORM-VET, 
2020). Three isolates carried blaCTX-M-55, blaCTX-M-24 and blaCTX-M-3, 
respectively. In addition, several other β-lactamase genes were detected 
among the isolates, such as blaTEM-1B, blaTEM-40, blaTEM-135, blaSHV-2, 
blaDHA-1, blaCMY-42 and blaOXA-1. Twelve CTX-M-producing E. coli strains 
also carried TEM-1B. VIM-1-producing isolate 3–349 carried several 
β-lactamases, such as CTX-M-15, TEM-1B, SHV-2 and OXA-1. 
3.6. Other clinically relevant ARGs, virulence genes and BMRGs detected 
in sequenced strains 
Among the sequenced E. coli isolates (n = 46), apart from β-lacta-
mases, the majority carried genes conferring resistance to sulfonamides 
(73.9%), aminoglycosides (71.7%), macrolides (65.2%), tetracyclines 
(63.0%), trimethoprim (60.9%), fluoroquinolones (32.6%) and pheni-
cols (26.1%) (Table 2). The most prevalent combination of ARGs 
detected in the sequenced isolates (n = 46) was observed in ten CTX-M- 
producing isolates, carrying dfrA17, sul1, sul2, tet(A), aph(6)-Id, aph 
(3’’)-Ib, aadA5, and mph(A). Notably, one CTX-M-14-producing isolate 
carried tet(X4) gene conferring resistance to tigecycline (Marathe et al., 
2021). In addition, 70% of the isolates (n = 32) had mutations in qui-
nolone resistance-determining regions (QRDRs) of gyrA and parC 
(Table 2), such as gyrA(S83L), explaining the high level of resistance 
observed against NAL and CIP (Hooper and Jacoby, 2015). 
The isolates carried several virulence factors, including aerobactin 
(iucA-D, iutA), ferrienterobactin (fepA-D, fepG, fes), salmochelin (iroB-E, 
iroN) and yersiniabactin siderophores (fyuA, irp1–2, ybtA/E/P/Q/S/U/ 
X), and type III (espL1/4, espR1/3, espX1–2, espX4–5, espY3–4) and type 
VI (tssA-C, tssF-G, tssJ/L/M) secretion systems (Supplementary 
Table S5). In addition, a few isolates harbored important toxins like 
cytotoxic necrotizing factor (cnf1), hemolysin (hlyA-D), genotoxin col-
ibactin (clbA, clbP) and Shigella enterotoxin (senB, set1A-1B), suggesting 
the pathogenic potential of these isolates (Garcia et al., 2013; Gu et al., 
2019; McCarthy et al., 2015). Along with virulence, many isolates 
harbored multiple BMRGs encoding resistance to acriflavine (acrA-B, 
acrE/envC, acrF/envD, acrR/ybaH), quaternary ammonium compounds 
(qacE/F, qacEΔ1, sugE), copper (pcoA, copA, cusA) and zinc (zntA, znuA, 
zraR) (Supplementary Table S6). A few isolates carried genes conferring 
resistance to silver (silA-C, silE-F, silP, silR-S) and mercury (merA-B, 
merD/P/T, merR1-R2). 
4. Discussion 
To the best of our knowledge, this is the first study performing a city- 
scale sewage surveillance of antibiotic resistance in E. coli strains, 
especially from Norway. Our study reveals the presence of clinically 
relevant carbapenemases and ESBLs like NDM-6, VIM-1, OXA-48- 
variant, CTX-M-15 and CTX-M-14, as well as tigecycline resistance 
gene tet(X4) in E. coli present in the local population in Bergen city, 
Norway, as well as in treated effluents from STPs. We also show that the 
resistance profiles and diversity of ESBLs detected in E. coli isolates 
Fig. 1. Resistance rates (%) of Escherichia coli isolated from influent (n = 300) and effluent (n = 262) samples collected from five sewage treatment plants in Bergen, 
Norway in August 2020 and October 2020, respectively. No resistance was observed for meropenem, tigecycline or colistin, hence these antibiotics were not included 
in the figure. 
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Table 2 
Sequence type (ST), antibiotic resistance genes (ARGs), and mutations in quinolone resistance-determining regions (QRDRs) of gyrA and parC detected in Escherichia 
coli isolates (n = 46) obtained from influent (Inf.) and effluent (Eff.) samples in this study.  
Isolate Sample 
type 
ST ARGs QRDRs 
2–10 Inf. ST744 blaTEM-1B, dfrA17, sul1, sul2, tet(B), aadA5, aph(3’’)-Ib, aph(6)-Id, catA1, mph(A) gyrA(S83L, D87N), parC 
(S80I) 
2–13 Inf. ST10 blaTEM-1B, dfrA5, sul2 – 
2–28 Inf. ST349 blaDHA-1, dfrA7, dfrA17, sul1, sul2, qnrB4, tet(A), aph(3’’)-Ib, aph(6)-Id, mph(A) – 
2–53 Eff. ST1380 blaTEM-1B, blaDHA-1, sul1, qnrB4, mph(A) – 
2–75 Inf. ST69 blaCTX-M-14, blaTEM-1B, dfrA14, mph(A) gyrA(S83L, D87N), parC 
(S80I) 
2–87 Inf. ST131 blaTEM-1B, dfrA17, sul1, sul2, tet(A), aph(6)-Id, aph(3’’)-Ib, aac(3)-Iid, mph(A) gyrA(S83L) 
2–106 Inf. ST46 blaOXA-1, tet(B), aadA1, catA1 – 
2–116 Inf. ST58 blaTEM-1B, dfrA5, sul2, tet(B), aph(6)-Id, aph(3’’)-Ib gyrA(S83L) 
2–165 Inf. ST131 blaCTX-M-27, blaDHA-1, dfrA17, sul1, sul2, qnrB4, tet(A), aph(3’’)-Ib, aph(6)-Id, mph(A) gyrA(S83L, D87N), parC 
(S80I) 
2–233 Inf. ST131 blaCTX-M-3, blaTEM-1B gyrA(S83L) 
2–301 Inf. ST131 blaCTX-M-27, dfrA17, sul1, sul2, tet(A), aph(3’’)-Ib, aph(6)-Id, aadA5, mph(A) gyrA(S83L) 
2–302 Inf. ST131 blaCTX-M-24, blaTEM-1B gyrA(S83L) 
2–307 Eff. ST131 blaCTX-M-27, dfrA17, sul1, sul2, tet(A), aph(6)-Id, aph(3’’)-Ib, aadA5, mph(A) gyrA(S83L) 
2–309 Inf. ST131 blaCTX-M-27, dfrA17, sul1, sul2, tet(A), aph(6)-Id, aph(3’’)-Ib, aadA5, mph(A) gyrA(S83L, D87N), parC 
(S80I) 
2–310 Inf. ST131 blaCTX-M-15, blaTEM-1B, blaOXA-1, aac(6’)-Ib-cr, aac(3)-IIe gyrA(S83L, D87N), parC 
(S80I) 
2–318 Inf. ST295 blaCTX-M-15, dfrA1, sul2, qnrS1, tet(A), aadA1, aph(3’’)-Ib, aph(6)-Id – 
2–320 Inf. ST69 blaCTX-M-15, qnrS1 – 
2–322 Inf. ST131 blaCTX-M-27, dfrA17, sul1, sul2, tet(A), aph(6)-Id, aph(3’’)-Ib, aadA5, mph(A) gyrA(S83L, D87N), parC 
(S80I) 
2–324 Inf. ST38 blaCTX-M-15, blaTEM-1B, dfrA7, dfrA12, sul1, tet(D), aadA2, aac(3)-IId, catA1, mph(A) gyrA(S83L, D87N), parC 
(S80I) 
2–326 Inf. ST167 blaCTX-M-14, dfrA12, sul2, qnrS1, tet(X4), tet(M), aph(6)-Id, aadA1, aadA2, ant(2’’)-Ia, aph(3’’)-Ib, cml, erm(B), erm 
(42) 
gyrA(S83L, D87N), parC 
(S80I) 
2–327 Inf. ST131 blaCTX-M-27, blaTEM-1B, dfrA17, sul1, sul2, tet(A), aadA5, aph(3’’)-Ib, aph(6)-Id, aac(3)-Iid, mph(A) gyrA(S83L) 
2–329 Inf. ST131 blaCTX-M-15, dfrA17, sul1, sul2, tet(A), aph(3’’)-Ib, aadA5, aph(6)-Id, mph(A) gyrA(S83L) 
2–331 Inf. ST167 blaNDM-6, blaTEM-1B, blaCMY-42, dfrA12, sul1, tet(A), aadA2, rmtB, mph(A) gyrA(S83L, D87N), parC 
(S80I) 
2–333 Inf. ST167 blaNDM-6, blaTEM-1B, blaCMY-42, dfrA12, sul1, tet(A), aadA2, rmtB, mph(A) gyrA(S83L, D87N), parC 
(S80I) 
2–335 Inf. ST10 blaCTX-M-15, qnrS1 gyrA(S83L) 
2–338 Eff. ST38 blaOXA-244, blaCTX-M-27, dfrA17, sul1, sul2, tet(A), aph(6)-Id, aph(3’’)-Ib, aadA5, mph(A) gyrA(S83L) 
2–343 Inf. ST131 blaCTX-M-15, blaOXA-1, tet(A), aac(6’)-Ib-cr, aac(3)-IIe gyrA(S83L, D87N), parC 
(S80I) 
2–345 Inf. ST1193 blaCTX-M-15, blaTEM-1B gyrA(S83L, D87N), parC 
(S80I) 
2–346 Inf. ST5044 blaCTX-M-55, sul2, qnrS4, tet(A), aph(6)-Id, aph(3’’)-Ib, floR – 
2–348 Inf. ST131 blaCTX-M-15, blaTEM-1B gyrA(S83L) 
3–178 Inf. ST11874a blaTEM-40 – 
3–304 Inf. ST69 blaCTX-M-27, blaTEM-1B, dfrA17, sul1, tet(A), aac(3)-IIe, aadA5, erm(B), mph(A) gyrA(S83L) 
3–315 Inf. ST38 blaCTX-M-14, blaTEM-1B, dfrA12, sul1, sul2, tet(D), aadA2, aph(3’’)-Ib, aph(6)-Id, mph(A) gyrA(S83L, D87N), parC 
(S80I) 
3–316 Inf. ST38 blaCTX-M-14, blaTEM-135, tet(A) – 
3–325 Inf. ST69 blaCTX-M-27, blaDHA-1, dfrA17, sul1, qnrB4, aadA5, mph(A) gyrA(S83L) 
3–338 Inf. ST11873a blaCTX-M-15, blaTEM-1B, blaOXA-1, sul2, qnrS1, aac(3)-IIe, aac(6’)-Ib-cr, aph(3’)-Ia, catB3, floR, mph(A) – 
3–341 Inf. ST11873a blaCTX-M-15, blaTEM-1B, blaOXA-1, sul2, qnrS1, aac(3)-IIe, aac(6’)-Ib-cr, aph(3’)-Ia, catB3, floR, mph(A) – 
3–343 Inf. ST11873a blaCTX-M-15, blaTEM-1B, blaOXA-1, sul2, qnrS1, aac(3)-IIe, aac(6’)-Ib-cr, aph(3’)-Ia, catB3, floR, mph(A) – 
3–344 Inf. ST131 blaCTX-M-14, blaTEM-1B, dfrA17, sul1, sul2, tet(A), aac(3)-IId, aadA5, aph(6)-Id, aph(3’’)-Ib, mph(A) gyrA(S83L, D87N), parC 
(S80I) 
3–346 Inf. ST131 blaCTX-M-27, dfrA17, sul1, sul2, tet(A), aph(6)-Id, aadA5, aph(3’’)-Ib, mph(A) gyrA(S83L, D87N), parC 
(S80I) 
3–347 Inf. ST131 blaCTX-M-15, blaTEM-1B, blaOXA-1, dfrA17, sul1, tet(A), aadA5, aac(3)-IIe, aac(6’)-Ib-cr, mph(A) gyrA(S83L, D87N), parC 
(S80I) 
3–348 Inf. ST131 blaCTX-M-27, blaTEM-1B, dfrA17, sul1, sul2, tet(A), aph(6)-Id, aph(3’’)-Ib, aadA5, aac(3)-Iid, mph(A) gyrA(S83L) 
3–349 Eff. ST635 blaVIM-1, blaCTX-M-15, blaTEM-1B, blaSHV-2, blaOXA-1, dfrA14, sul1, sul2, qnrB1, tet(A), aph(3’’)-Ib, aph(6)-Id, aac(6’)- 
Ib4, aph(3’)-XV, aac(3)-IIe, catA1 
– 
3–354 Eff. ST131 blaCTX-M-15, blaTEM-1B, blaOXA-1, dfrA17, sul1, tet(A), aac(6’)-Ib-cr, aac(3)-IIe, aadA5, mph(A) gyrA(S83L, D87N), parC 
(S80I) 
3–355 Inf. ST1380 blaTEM-1B, blaDHA-1, sul1, qnrB4, mph(A) – 
3–360 Inf. ST38 blaCTX-M-14, sul2, aph(3’’)-Ib, aph(6)-Id gyrA(S83L), parC(S80I)  
a Novel sequence type. 
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obtained from sewage resembled the clinical prevalence in Norway. 
NDM-6 was detected in two isolates (2–331 and 2–333) from influent 
(Table 2). They belonged to ST167, which is a known pathogenic 
sequence type of E. coli, usually associated with extra-intestinal in-
fections (Manges et al., 2019). In accordance, these isolates harbor 
several virulence factors, including ferrienterobactin and yersiniabactin 
siderophores, type III and type VI secretion systems, suggesting potential 
for virulence (Johnson et al., 2018; Navarro-Garcia et al., 2019). 
Although, NDM-5-producing E. coli belonging to ST167 has previously 
been detected, NDM-6 has so far not been reported from the clinics in 
Norway (NORM/NORM-VET, 2020). Our findings thus, provide 
important insights into the current resistance situation within the local 
population, revealing the presence of clinically relevant carbapene-
mases in pathogenic E. coli strains, that are prevalent in the clinics in 
other countries (Dadashi et al., 2019). 
We also detected carbapenemases OXA-244 and VIM-1 in two iso-
lates (2–338 and 3–349, respectively) from effluent (Table 2). The OXA- 
244-producing isolate belonged to the high-risk clone ST38, which is 
widespread globally and responsible for causing urinary tract infections 
(Manges et al., 2019). This isolate also carried multiple virulence fac-
tors, such as ferrienterobactin and yersiniabactin siderophores, type III 
and type VI secretion systems (Supplementary Table S5), indicating the 
potential for virulence. Outbreaks with OXA-244-producing E. coli ST38 
has recently been reported from Bergen, Norway (UNN, 2020). This 
highlights the importance of city-scale sewage surveillance of antibiotic 
resistance for providing up-to-date knowledge on the local resistance 
situation. Although the VIM-1-producing isolate belonged to the 
commensal ST635, blaVIM-1 gene is mobile and can be transferred be-
tween different pathogens (Arcari et al., 2020). The clinical prevalence 
of VIM-variants in Norway have remained largely stable, while 
NDM-variants and OXA-48-variants have had a gradual increase during 
the last ten years (NORM/NORM-VET, 2020). Two 
carbapenemase-producing isolates obtained from effluent suggests that 
clinically relevant carbapenemases are introduced into the receiving 
environment through sewage pollution (Lamba et al., 2018; Karkman 
et al., 2019; Marathe et al., 2019). This may contribute to environmental 
transmission of clinically important ARGs conferring resistance to 
last-resort antibiotics (Marathe et al., 2017). Along with large amounts 
of fecal material, sewage also contains considerable amounts of other 
antimicrobial agents, such as biocides and heavy metals (Östman et al., 
2017). These agents are widely used in healthcare and agriculture, and 
would inevitably end up in sewage treatment systems as well as the 
environment (Wang and Liang, 2021; Rehman et al., 2019). Heavy metal 
pollution has been observed in the marine environment in Norway, 
especially in areas close to aquaculture and mining activities, thereby 
contributing to possible selection pressure (IMR, 2021). The 
VIM-1-producing isolate carried several BMRGs, including genes 
conferring resistance silver, copper and mercury (Supplementary 
Table S6), suggesting the potential for persistence and spread of this 
isolate in the marine environment (Yuan et al., 2019). 
Besides detecting carbapenemase-producing E. coli, pathogenic 
strains carrying different CTX-M-type ESBLs were also detected in in-
fluents and treated effluents that are entering the receiving environ-
ment. In Norway, CTX-M-type ESBLs have emerged as a significant 
clinical problem (NORM/NORM-VET, 2020). Among CTX-M-producing 
isolates in our study, blaCTX-M-15 was most frequently detected, followed 
by blaCTX-M-27 and blaCTX-M-14. The prevalence of CTX-M-type ESBLs 
detected in our isolates was similar to the pattern reported from the 
clinical E. coli isolates from 2019 in Norway (NORM/NORM-VET, 2020), 
suggesting that the diversity of ESBLs observed among the E. coli isolates 
obtained from influent, thus, potentially reflects the current local 
resistance situation (Hutinel et al., 2019; Huijbers et al., 2020). Most of 
the CTX-M-producing isolates in our study belonged to pathogenic STs, 
such as 131, 38 and 69 that are known to cause extra-intestinal in-
fections (Manges et al., 2019). In Norway, most of the clinical isolates of 
ESBL-producing E. coli obtained from blood samples (n = 141) in 2019 
belonged to ST131 (56.7%), followed by ST38 (5.0%) (NORM/-
NORM-VET, 2020), suggesting that these high-risk clones are important 
for the dissemination of CTX-M-type ESBLs in Norway (Grevskott et al., 
2020; Paulshus et al., 2019). In addition, four isolates belonging to two 
novel STs of E. coli were detected in our study (Table 2). Among these, 
one isolate (3− 178) belonging to novel ST11874 carried multiple 
virulence factors, including cytotoxic necrotizing factor 1, genotoxin 
colibactin ClbA-Q, hemolysin A-D, as well as ferrienterobactin, sal-
mochelin, aerobactin and yersiniabactin siderophores, indicating that 
this isolate belonging to novel ST may represent a potential pathogen 
that may cause significant public health concern in future (Gu et al., 
2019; McCarthy et al., 2015; Johnson et al., 2018). 
Reduction in the number of cefotaxime-resistant E. coli and total 
E. coli in the effluents was observed for all five STPs (Supplementary 
Table S1). For Fle and Kn, there was complete reduction in the number 
of cefotaxime-resistant E. coli isolates during both occasions, while for 
KvÅ there was complete reduction in the number of cefotaxime-resistant 
E. coli isolates in effluent from October sampling. Although Hol is the 
only site that receives hospital sewage (Table 1), the number of 
cefotaxime-resistant E. coli isolates in influent and effluent of this STP 
did not differ compared to the other STPs. However, clinically important 
metallo-β-lactamases like NDM-6 and VIM-1, as well as tigecycline 
resistance gene tet(X4), were detected only in this treatment plant. The 
resistance profiles of E. coli isolates obtained from influent samples were 
similar, but a fold lower than, the clinical prevalence in Norway (Sup-
plementary Table S2). A possible explanation for the observed differ-
ences in resistance rates is that the clinical prevalence of resistance is 
based on E. coli strains causing infections, while isolates obtained from 
influents predominantly originate from the local population connected 
to the sewage system and may represent both pathogenic and 
commensal E. coli strains (Clermont et al., 2017). Nevertheless, the 
resistance pattern observed in the E. coli isolates obtained from influents 
in August and October sampling mimicked the clinical prevalence in 
Norway (NORM/NORM-VET, 2020). Our study thus, provides important 
insights into the resistance situation in the local population. 
5. Conclusion 
Our study highlights the importance of sewage-based surveillance of 
antibiotic resistance, in order to understand the current resistance sit-
uation in the population. It demonstrates the presence of clinically 
relevant carbapenemases, such as NDM-6, VIM-1 and OXA-244, in E. coli 
isolates obtained from influents and effluents collected from Bergen city 
in Norway. Norway has a very low prevalence of carbapenem-resistance, 
as well as a low usage of last-resort antibiotics (NORM/NORM-VET, 
2020). Detection of clinically important carbapenemases in sewage 
emphasizes the need for population-based sewage surveillance of 
resistance in order to understand the local resistance situation and to 
predict future local outbreaks. Our study may thus, provide a framework 
for population-based surveillance of antibiotic resistance, especially in 
Norway. 
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